MKM Starts Amylin (AMLN) at Neutral, Sets $13 Price Target
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 19
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 19
Join SI Premium – FREE
An analyst at MKM Partners initiated coverage on shares of Amylin Pharmaceuticals (NASDAQ: AMLN) with a Neutral rating and a $13 price target earlier.
With Amylin shares down about 3 percent to $11.75 Friday morning, MKM's new price target represents potential upside of about 11 percent.
For more ratings news on Amylin Pharmaceuticals click here and for the rating history of Amylin Pharmaceuticals click here.
With Amylin shares down about 3 percent to $11.75 Friday morning, MKM's new price target represents potential upside of about 11 percent.
For more ratings news on Amylin Pharmaceuticals click here and for the rating history of Amylin Pharmaceuticals click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wedbush Starts Immunic Inc. (IMUX) at Outperform
- Goldman Sachs Resumes Luxshare Precision (002475:CH) at Buy
- ThinkEquity Starts Deep Isolation Nuclear (DBHL) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
